PACAB-002 is engineered to prevent recurrence in ovarian cancer
PACAB-002 is engineered to target peritoneal micrometastases that are difficult to eradicate with current standard-of-care treatment. This is an important challenge in ovarian cancer, as intraperitoneal recurrence is a key driver of poor survival.
The European Medicines Agency (EMA) has granted orphan drug designation to PACAB-002 for treatment of ovarian cancer. With this designation, EMA recognises the strong preclinical efficacy data of PACAB-002 and its potential to provide a clinically relevant benefit over existing treatment options for patients with ovarian cancer.
Ovarian cancer has high recurrence caused by peritoneal micrometastases
Systemic treatment is not sufficient to eradicate micrometastases located in the peritoneal cavity. Intraperitoneal administration of chemotherapy has indicated efficacy, but rapid drainage significantly limits effective dose and increases systemic toxicity.
PACAB-002 combines NaDeNo’s technology with an established drug that has known antitumor efficacy
PACAB-002 combines NaDeNo’s technology and an established drug with known antitumor efficacy
Biodegradeable polymer matrix encapsulating the molecule without any chemical modification, while protecting it from degradation until it is released.
Encapsulated active pharmaceutical ingredient (API) of PACAB-002, cabazitaxel, a second-generation taxane with proven efficacy.
Surface chemistry for preferential tumor accumulation and retention, with 10-fold higher tumor exposure in preclinical studies.
In this preclinical ovarian cancer model, a single intraperitoneal dose of PACAB-002 doubled median survival compared with free drug at the same dose, while all animals receiving two doses were alive at day 100 (pre-defined study end).
PACAB-002 shows peritoneal retention, tumor accumulation and survival benefit in preclinical studies
2X PACAB-002
1X PACAB-002
All animals alive at day 100
Free drug
40 days
81 days
Untreated
25 days